High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG-, and 5.0% IgM-IgG+). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:222 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 222(2020), 12 vom: 13. Nov., Seite 1955-1959 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Naranbhai, Vivek [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.12.2020 Date Revised 30.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiaa579 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31478747X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31478747X | ||
| 003 | DE-627 | ||
| 005 | 20240330232829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiaa579 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM31478747X | ||
| 035 | |a (NLM)32906151 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Naranbhai, Vivek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2020 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, which is especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts, by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG-, and 5.0% IgM-IgG+). Of the 200 participants, 50.5% reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Chelsea Massachusetts | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a immunoassay | |
| 650 | 4 | |a lateral flow assay | |
| 650 | 4 | |a seroprevalence | |
| 650 | 4 | |a serosurveillance | |
| 650 | 4 | |a validation | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 700 | 1 | |a Chang, Christina C |e verfasserin |4 aut | |
| 700 | 1 | |a Beltran, Wilfredo F Garcia |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Tyler E |e verfasserin |4 aut | |
| 700 | 1 | |a Astudillo, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Villalba, Julian A |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Gelfand, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, Bradley E |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Jared |e verfasserin |4 aut | |
| 700 | 1 | |a Hauser, Blake M |e verfasserin |4 aut | |
| 700 | 1 | |a Caradonna, Timothy M |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Galit |e verfasserin |4 aut | |
| 700 | 1 | |a Murali, Mandakolathur R |e verfasserin |4 aut | |
| 700 | 1 | |a Jasrasaria, Rashmi |e verfasserin |4 aut | |
| 700 | 1 | |a Quinlan, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Xerras, Dean C |e verfasserin |4 aut | |
| 700 | 1 | |a Betancourt, Joseph R |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, David N |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Aaron G |e verfasserin |4 aut | |
| 700 | 1 | |a Lennerz, Jochen |e verfasserin |4 aut | |
| 700 | 1 | |a Poznansky, Mark C |e verfasserin |4 aut | |
| 700 | 1 | |a Iafrate, A John |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 222(2020), 12 vom: 13. Nov., Seite 1955-1959 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:222 |g year:2020 |g number:12 |g day:13 |g month:11 |g pages:1955-1959 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiaa579 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 222 |j 2020 |e 12 |b 13 |c 11 |h 1955-1959 | ||